A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Infinity Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00761696
First received: September 25, 2008
Last updated: June 19, 2012
Last verified: June 2012
  Purpose

The primary objectives of the study are:

  • To determine the safety and the maximum tolerated dose (MTD) of IPI-926
  • To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s)
  • To recommend a dose and schedule of IPI-926 for subsequent studies

Condition Intervention Phase
Neoplasms
Drug: IPI-926
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

Resource links provided by NLM:


Further study details as provided by Infinity Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • To determine the safety and the maximum tolerated dose (MTD) of IPI-926 [ Time Frame: 6mths to 1 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To evaluate the anti-tumor activity of IPI-926 [ Time Frame: 6mths to 1 year ] [ Designated as safety issue: Yes ]

Enrollment: 94
Study Start Date: September 2008
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IPI-926
Oral daily dosing
Drug: IPI-926
Oral daily dosing
Other Name: Hedgehog pathway inhibitor

Detailed Description:

Study IPI-926-01 is a Phase 1, open-label, dose-escalation study in patients with advanced and/or metastatic solid tumor malignancies.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Pathologically confirmed diagnosis of a solid tumor for which no standard therapy proven to provide clinical benefit is available.
  2. ≥18 years of age
  3. Life expectancy of at least 3 months.
  4. ECOG performance status of 0 to 2.
  5. Ability to follow the study and all protocol requirements.
  6. Voluntarily sign an informed consent form
  7. Women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation of who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative serum or urine pregnancy test prior to treatment. All WCBP, all sexually active male patients, and all partners of patients must agree to use adequate methods of birth control throughout the study.
  8. Recovery to </= Grade 1 or baseline of any toxicities due to prior treatments, excluding alopecia.

Exclusion Criteria:

  1. Treatment with following therapies as indicated:

    • Any chemotherapy (other than nitrosoureas or mitomycin C), radiation therapy, surgery, hormonal therapy, or investigational therapy within 4 weeks of the start of IPI-926 administration. Patients with luteinizing hormone releasing hormone therapy.
    • Any tyrosine kinase inhibitor (e.g. erlotinib, imatinib) within 2 weeks of the start of IPI-926 administration
    • Nitrosoureas o or mitomycin C within 6 weeks of the start of IPI-926 administration.
  2. Inadequate hematologic function - neutrophil count (ANC) <1,500 cells/mm3, platelet count <100,000/mm3, or hemoglobin <9.0 g/dL (may be increased to this level with transfusion as long as there is no evidence of active bleeding).
  3. Inadequate hepatic function - aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 x upper limit of normal (ULN); >5 x ULN if attributable to liver metastases; total bilirubin >1.5 x ULN.
  4. Inadequate renal function - serum creatinine >1.5 x ULN.
  5. Uncontrolled hypomagnesemia or hypokalemia, defined as ≥ Grade 3 despite adequate electrolyte supplementation.
  6. Baseline QTcF >450 msec in men or >470 msec in women.
  7. Concurrent treatment with any agent known to prolong the QTc interval.
  8. Prior surgery affecting drug absorption or any gastrointestinal dysfunction that could alter drug absorption (e.g. gastric bypass, Whipple procedure, gastrectomy).
  9. History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months.
  10. Venous thromboembolic event (e.g. pulmonary embolism or deep vein thrombosis) requiring anticoagulation or who meet any of the following criteria are excluded:

    • have been on a stable dose of anticoagulation for <1 month
    • have had a Grade 2, 3 or 4 hemorrhage in the last 30 days
    • experiencing continued symptoms from venous thromboembolic event (e.g. continued dyspnea or oxygen requirement) *Past venous thromboembolic event but do not meet any of the above three criteria are eligible for participation.
  11. History of a seizure within the last 10 years or seizure disorder requiring anti-epileptic medications.
  12. Concurrent treatment with medications known to lower the seizure threshold.
  13. Concurrent administration of the medications or foods which are known to inhibit or induce CYP3A activity to a clinically relevant degree.
  14. Presence of active infection or systemic use of antibiotics within 72 hours of treatment.
  15. Significant co-morbid condition or disease which in the judgment of the Investigator would place the patient at undue risk or interfere with the study.
  16. Known immunodeficiency virus (HIV) positivity.
  17. Pregnant or lactating women.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00761696

Locations
United States, Arizona
TGen Clinical Research Service at Scottsdale Healthcare
Scottsdale, Arizona, United States, 85258
United States, California
Stanford University
Redwood City, California, United States, 94063
United States, Colorado
University of Colorado Health Science Center
Aurora, Colorado, United States, 80045
United States, Maryland
Johns Hopkins Uninversity
Baltimore, Maryland, United States, 21231
Canada, Quebec
McGill University Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Sponsors and Collaborators
Infinity Pharmaceuticals, Inc.
Investigators
Study Director: Robert Ross, MD Infinity Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Infinity Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00761696     History of Changes
Other Study ID Numbers: IPI-926-01
Study First Received: September 25, 2008
Last Updated: June 19, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Infinity Pharmaceuticals, Inc.:
solid tumor malignancies

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on October 23, 2014